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Abstract 
The genetic association between autism spectrum disorder (ASD) and psychotic disorders 
such as schizophrenia is complicated and mirrors the clinical overlap between these 
conditions to some degree. However, no studies to date have examined the genetics of 
individuals dually diagnosed with both ASD and psychosis. In this study, we present findings 
of copy number variants (CNVs) from a study of 116 well-characterised individuals with this 
dual diagnosis. DNA was extracted and arrayed using the Affymetrix CytoScan HD 2.8M 
array or the Affymetrix Cytogenetics arrays and compared with existing samples from the 
Database of Genomic Variants and the Simons Simplex Collection of CNVs from individuals 
with ASD and their families. Twenty-seven novel CNVs ≥ 20k base pairs were identified in 
the sample, most occurring in only a single individual, although two were found in two 
female participants. Forty-nine rare CNVs (<1.5% rate in general population) were also found 
at significantly higher frequencies than expected. The findings may provide evidence for 
areas of further study in the understanding of the development of both ASD and psychosis 
due to the number of affected genetic regions that have not previously been linked to these 
conditions. 
 
Introduction 
Schizophrenia, psychotic bipolar disorder, and atypical psychoses all occur in people 
with autism spectrum disorder (ASD) (Larson et al., 2017). Psychosis and ASD have a 
complex historical relationship that has lumped them into one disorder and then split them 
again over time. Bender (1953) argued that any distinction between the two was false and that 
schizophrenia and ASD were manifestations of the same diathesis. This view has been argued 
more recently with regard to overlapping cognitive profiles such as impaired theory of mind 
and schizotypal traits (de Lacy and King, 2013; Hommer and Swedo, 2015). A number of 
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individuals with psychosis, particularly schizophrenia, meet criteria for ASD (Hallerback et 
al., 2012; Lugnegård et al., 2014). Prevalence of psychosis in ASD populations, while 
difficult to establish, has been found to be higher than 25% in one study (Mouridsen et al., 
2008) and is generally found to be elevated across studies in this area. However, the overlap 
is difficult to investigate epidemiologically because any condition affecting social interaction 
will have a different impact in early childhood when relationships and personality are 
forming than in later childhood or adolescence when relationships and social identity are 
much more established. Indeed, differences in social interaction throughout childhood have 
been described in longitudinal studies of children who will, as adults, develop schizophrenia 
(Jones et al., 1994). 
As phenotypic differences cannot resolve the question of whether there is a common 
ASD/psychosis diathesis, the next step is to consider genetic overlap.  This genetic overlap 
remains poorly understood however. Some models suggest that 20-75% of genetic variance is 
shared by ASD and schizophrenia, and that shared by ASD and bipolar disorder is 20-60% 
(Rzhetsky et al., 2007), but no single site has been identified and the modelling cannot predict 
which elements of the genome are shared or what form the variance will take (e.g. structural 
or functional variation). Work carried out by the Cross-Disorder Group of the Psychiatric 
Genomics Consortium on functional variants (single nucleotide polymorphisms; SNPs) has 
begun to identify specific shared variation (Cross-Disorder Group of the Psychiatric 
Genomics Consortium, 2013). It seems likely that the shared risk conferred by SNPs is due to 
rare variants of large effect, rather than common variants of cumulative effect (Boyle et al., 
2017). 
There is also emerging evidence of shared structural variation in schizophrenia and 
ASD, in the form of copy number variants (CNVs), regions of DNA that are either duplicated 
one or more times, or where one or both copies are missing (Crespi and Crofts, 2012). 
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However, there do seem to be fundamental differences between the CNVs observed in the 
separate populations. For example, CNVs seem to be much more penetrant in ASD cases 
versus schizophrenia cases (Kirov et al., 2014). It has also been argued that there are sites 
where the nature of the CNV (gain or loss) dictates the disorder that emerges (Crespi and 
Crofts, 2012), although there has been no work conducted to assess whether these different 
structural variations result in different functional outcomes. 
Genetic studies to date have focused on individuals with either ASD or psychosis, 
commonly dividing the latter into schizophreniform and affective variants. There is also 
evidence of sites with linkage to both conditions (chromosome 22q11.2, chromosome 15q11-
q13 (see Vorstman (2006) for a discussion) that would logically suggest shared susceptibility 
and increased risk of co-morbidity. A recent study of 22q11.2 deletion, however, found that 
the CNV did not necessarily give rise to the development of both conditions in a longitudinal 
study (Fiksinski et al., 2017). This highlights the possibility of other factors (genetic or 
environmental) that links to the development of a disorder and further research is needed in 
this area. There are no previously published studies examining the genetics of individuals 
dually diagnosed with ASD and co-morbid psychosis. In the current study, we present an 
analysis of CNVs affecting 116 people with dual diagnosis of ASD and psychosis (affective, 
schizophrenic, and atypical - for a full clinical description of this cohort, please see Larson et 
al. (2017)). By studying individuals dually affected, we hope to further clarify the nature of 
the genetic relationship between the two conditions. The research was premised upon the 
prediction that rare CNVs (present in less than 1% of a general population sample listed on 
the Database of Genomic Variants [DGV]) would play a role in the aetiology of co-occuring 
ASD and psychosis. In particular, we predicted that CNVs overlapping chromosome 15q11-
q13, a region associated with Prader-Willi Syndrome (a neurodevelopmental disorder 
characterised by high rates of psychosis (Soni et al., 2008)) and ASD would be implicated in 
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those dually diagnosed with ASD and psychosis. In addition, we hypothesised that key genes 
that have been identified as aetiologically important to both ASD and psychosis separately 
would be more often affected by rare CNVs in people who have both conditions than in 
people in the general population or those with ASD only. We also examine the role that 
CNVs overlapping other genes identified as important to ASD or psychosis separately in 
people with ASD and co-morbid psychosis. 
 
Materials and Methods 
This study took place between January 2011 and April 2014. It was approved by the 
Norfolk Research Ethics Committee in the United Kingdom (UK). All participants either 
gave informed consent, or, where they were found to lack capacity to consent following UK 
guidelines, a consultee was identified to advise on their behalf. People who lacked capacity to 
consent were only included when they had regular blood tests as part of their clinical care and 
a sample could be obtained as part of this for genetic study. 
 
Recruitment and participants 
Participants were recruited from clinical services in the public and independent 
sectors in the UK, as well as from charities and an Asperger’s syndrome social networking 
website. Presence of both ASD and psychosis were confirmed using standardized methods. 
For a full description of the clinical characteristics and methods of ascertainment, please see 
Larson et al. (2017). A total of 116 individuals with a confirmed dual diagnosis of ASD and 
psychosis were recruited for this study. While this is a comparatively small number of 
participants in the field of psychiatric research, the thorough characterisation of the sample 
and their relative rarity make this sample unique. 
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Genetic testing and CNV calling 
DNA was extracted from whole blood samples and tested for quality. DNA was 
arrayed on either the Affymetrix CytoScan HD 2.8M array or the Affymetrix Cytogenetics 
array (Affymetrix, Santa Clara, CA, USA). Affymetrix ceased production of the CytoScan 
array after the study had started, necessitating the change. Comparisons were made with data 
available from the Simon’s Simplex Collection (SSC) of people with ASD (N=1124), arrayed 
on the Illumina Human1M array (for full details of the methods used, see (Sanders et al., 
2011)). This group will be referred to as ASD-No Psychosis (ASD-NP). ASD-NP samples 
had been genotyped using the Illumina Human1M array and screened for rare CNVs prior to 
the data being made available to use for comparison.  
CNVs in the ASD-P group were called using the SNP-FASST2 Segmentation 
algorithm in the Nexus Copy Number 7 software (BioDiscovery, Hawthorne, CA, USA), 
with a significance threshold of 1x10-8. CNVs were also called using Affymetrix 
Chromosome Analysis Suite, (ChAS) using the inbuilt proprietary algorithm with default 
settings. CNVs are presented here if there was an area of overlap between calls from both 
algorithms – only the area of overlap defined by both algorithms with a minimum of five 
markers forms the reported CNVs in this study. A minimum size of 20kbp for calls was 
selected to enhance reliability of calls and also identify events likely to be rare, based on 
finding that the most common CNVs are smaller than 10kbp (McCarroll et al., 2008). 
Although this size is somewhat arbitrary, we consider it to strike a balance between screening 
out common genetic “noise” and not excluding the majority of CNVs of interest to this study. 
CNVs were compared with results listed on the DGV (up to October 2017) and included in 
this study if they were rare (reported in less than 1.5% of the population studied in the DGV) 
or unique (not reported on the DGV). 
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Additionally, a list of key genes previously implicated in ASD and/or psychosis was 
generated for targeted search in our results, using the AutWorks database 
(http://autworks.hms.harvard.edu/) (Nelson et al., 2012), and forms Supplement 1. The list 
was generated using the following disease terms in the database: “bipolar disorder”, 
“schizophrenia” and “psychotic disorders”. CNVs overlapping these genes were considered 
potentially relevant to ASD and/or psychosis. 
All comparison reported between groups remained significant after correction using 
the Benjamini-Hochberg/False-Discovery Rate (FDR) method. 
Results 
Overall CNV Rates 
The median number of CNVs larger than 20kbp present in individuals in the ASD-P group 
was 15 (range: 0-107). Two individuals did not carry a single confirmed CNV of larger than 
20kbp.  
Unique CNVs 
Twenty-seven CNVs larger than 20kbp that occurred in the ASD-P group were 
unique, meaning that they were unreported on the DGV and also unreported in the ASD-NP 
data. Most of these CNVs were only present in a single member of the ASD-P group and 
contained no genes from the AutWorks database search. Only one unique CNV contained a 
gene that appeared on the list of key genes generated from the Autworks database. This was a 
22kbp gain affecting chromosome 6p21.32 and contained SYNGAP1, a gene with a known 
link to autism (Berryer et al., 2013). It occurred in a participant with normal-range IQ. Two 
participants shared two unique CNVs (details are presented in Table 1 below, including brief 
clinical information). Both of these cases had a similar total number of CNVs detected (22 
and 28). 
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Table 1. This table shows a unique CNV not previous reported in the literature identified in two participants in the ASD-P 
group and not in the ASD-NP group. A brief clinical description is given of the cases. 
Chr Size (bp) CNV Type Gene(s) Clinical 
information 
6p21.32 40,180 Gain COL11A2, RXRB, SLC39A7, HSD17B8 Both participants 
with this gain were 
female, with normal 
range IQ, psychosis 
onset in early 20s, 
atypical psychosis 
with a strong 
affective component. 
20 24,010 Gain CDH4 
 
Unique CNVs present in only a single member of the cohort are presented in Supplement 2, 
also including brief clinical information. Notably, one of these was a duplication of the 
Prader-Willi Syndrome critical region of chromosome 15q. 
 
Rare CNVs 
In addition to unique CNVs, we also investigated the occurrence of rare CNVs 
(<1.5% frequency in large general population samples) in the ASD-P group. We found a 
number of rare CNVs (N=34) that were also present in cases and their families in the ASD-
NP data set, suggesting primarily an association with ASD, rather than specifically the 
comorbidity with psychosis. However, many rare CNVs were not found in the ASD-NP data 
and were significantly more frequently found in the ASD-P group than in the general 
population (N=49). Of these, only a small number contained genes previously identified as of 
interest to ASD or psychosis. Table 2 summarises rare CNVs found in more than one 
individual in the ASD-P group (n=18), giving the FDR-corrected p-value of the difference 
between the rate in the ASD-P group and rate found in the general population sample with the 
most frequent occurrence of this CNV reported on the DGV. Supplement 3 shows rare CNVs 
present in a single ASD-P participant along with Fisher’s exact comparison with the highest 
reported frequency of this variant in the DGV. 
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Table 2. Table showing the frequency of rare CNVs not found in the ASD-NP group. P-values are shown for Fisher’s exact 
testing comparing rates of the CNV in the ASD-P cohort and general population data available on the Database of Genomic 
Variants. Pseudogenes are included if they were overlapped by a CNV that also overlapped a gene. 
Chr Size (bp) CNV 
Type 
Gene(s) Frequency ASD-
P 
FDR-corrected 
p-values ⱡ 
1p36.33 51,504 Loss AGRN, RNF223, C1orf159 2/116 0.007 
 
2q11.2 
2q14.2 
112,727 
29,204 
Gain 
Gain 
ANKRD36 
GLI2 
8/116 
3/116 
0.002 
0.002 
2q21.1 27,568 Gain ANKRD36B 4/116 0.003 
6p11.2 20,932 Gain PRIM2 2/116 <0.001  
7p22.1 25,295 Gain CCZ1, RSPH10B2, RSPH10B 2/116 0.001 
10p12.33 156,336 Gain MRC1, TMEM236, MIR511-1, 
MIR511-2 
2/116 0.02 
10q11.22 24,049 Gain LOC643650 9/116 <0.001 
10q22.3 43,022 Gain ZMIZ1 3/116 <0.001 
10q23.2 94,341 Gain FAM35A 2/116 0.02 
11q11 41,984 Gain TRIM51 2/116 0.001 
11q14.1 31,919 Loss DLG2 2/116 0.01 
15q11.2 106,346 Gain PWRN2 3/116 0.003 
16p13.3 57,904 Loss RAB40C, WFIKKN1, C16orf13, 
FAM195A, WDR90, RHOT2, 
RHBDL1 
7/116 <0.001 
16p11.2 876,949 Gain SLC6A10P, TP53TG3B, TP53TG3, 
LOC390705 
4/116 <0.001 
16q22.1 155,025 Gain PDXDC2P, MIR1972-2, MIR1972-1, 
PDPR 
2/116 0.02 
19p13.2 61,990 Loss EMR4P, FLJ25758 2/116 0.01 
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Discussion 
 There are a number of limitations to the work presented here that should be addressed. 
The small sample size is unusual for genetic research, particularly in the era of cross-border 
collaboration such as that demonstrated by the Psychiatric Genomics Consortium, who can 
boast sample sizes in the tens of thousands. It is our assertion that people with comorbid 
psychosis and ASD are special, however, in that it seems reasonable to assume they are 
particularly genetically affected in order to have not one but two rare conditions. We would 
also argue that phenotypically, they represent a more well-defined group than the large 
datasets used in GWAS studies. The fact that any significant results were found given such a 
relatively small sample size seems to support our assertions. 
 It was also clearly less than ideal to compare with samples arrayed using different 
chips and in different labs. However, many studies published in the field rely on being able to 
use publically available data, and the difficulties surrounding identifying suitable comparison 
samples should not be underestimated. We felt that the ASD-NP data set was large enough to 
overcome difficulties with heterogeneity of ASD, and that using the DGV gave robust 
estimates of rates of CNVs in the general population. By restricting ourselves to what would 
be considered moderate or large CNVs, we hope to have removed much of the “noise” likely 
to be generated by different methods, materials, and so on. Smaller CNVs are much more 
susceptible to differences in array or calling techniques. 
Our study has demonstrated, in line with our hypotheses, that there are  differences 
between the CNVs observed in the ASD-P group versus the general population or the ASD-
NP group. A number of rare or unique CNVs were present in people with ASD-P. However, 
we found only limited evidence for the presence of high-confidence CNVs overlapping genes 
of known interest to the aetiology of ASD, psychosis, or both conditions. This raises the 
possibility that some of the rare or unique CNVs found in the ASD-P population may be of 
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interest to those seeking to understand the aetiology of both ASDs and psychosis, perhaps 
because they are unique indicators of risk of the comorbidity. It is also interesting to note that 
the majority of the rare and unique CNVs found in the ASD-P group were duplications. Itsara 
and colleagues (Itsara et al., 2009) reported higher rates of deletions than duplications in 
CNVs smaller than 100kbp in a general population sample, while the converse was true in 
our sample. There are several possible reasons why this might be the case. For example it 
could be as a result of “amplifications” of existing, smaller genetic defects in the parent or 
parents of individuals with ASD-P, or it could be a hallmark of a different pathological 
processes to those seen in deletions. Molecular and expression studies would be useful in 
clarifying this point, although it is known that duplications can have similarly significant 
effects to duplications (Ionita-Laza et al., 2009). 
 Our hypothesis regarding elevated rates of CNVs affecting 15q11-q13 and the 22qDS 
region was not supported, although we found a single case of each CNV in this cohort. This 
is surprising, as these are the two highest frequency regions with known associated to both 
ASD and psychosis. Given this was a small study, it is possible that it was underpowered to 
detect these CNVs, but it seems odd that other rare or unique CNVs should be represented 
more frequently. It is possible that individuals with known genetic abnormalities may have 
participated in the research due to already being involved with clinical genetic services, 
which could have biased results. This seems unlikely to have had a major impact on the 
results given the small number of individuals in the UK who have confirmed genetic 
abnormalities. 
It is also interesting that there was such a range of CNV burden across participants, as 
this is another potential factor that may be relevant to the comorbidity developing. The 
median number of CNVs larger than 20kbp was 15, but nine participants had at least twice 
this number, up to a maximum of 107. We do not know, from this study, whether these are de 
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novo or inherited.  We cannot draw any conclusions from the present study what this 
difference might mean but it is possible that a high rate of CNV simply increases the 
possibility of hits on multiple genes with differing genetic effects.  
 Our results indicate that rare and unique CNVs may play a role in the aetiology of co-
morbid psychosis and ASD, as well as possibly the overall large CNV burden. Two rare 
CNVs in the current study contained genes that were already known to be related to ASD, 
psychosis, or both conditions – MTNR1A, FAT1, SYNGAP1, and RELN. MTNR1A- and 
FAT1-affecting deletions have been reported previously, linked to ASD (Vona et al., 2014) 
and a rare variant of FAT1 has been linked to bi-polar disorder (Belmonte Mahon et al., 
2011). Mutations affecting melatonin receptors (of which MTNR1A is one) have been found 
in individuals with ASD, but their impact on ASD risk has been proposed to be minimal due 
to the frequencies of mutations found in healthy control populations (Chaste et al., 2010). The 
functional impact of a duplication affecting MTNR1A is currently unknown. However, the 
genes highlighted by our results are generally not currently implicated in any disease process, 
or are linked to unrelated conditions. We would suggest that this could be due to several 
factors: 1) the CNVs found may be rare but have a large effect on the brain that increases 
vulnerability to ASD and psychosis, or 2) they may have no phenotypic impact linked to 
ASD and/or psychosis. Further evidence is needed to improve understanding of the function 
of the genes highlighted in the current study. The results suggest a direction for future study 
for those seeking to understand the genetic basis for co-morbid ASD and psychosis. 
Out study is unusual in having very well-characterised participants who have not been 
previously studied. It is likely that it would be under-powered to find significant CNVs, and 
so the fact that any CNVs of interest have been identified at all indicates that this is a 
population with rich genetic variation. In particular, the two female participants with the 
same CNVs not reported in the general population, are of interest as this hints that, even in 
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such a small population, common potentially pathological CNVs are present. Our hope is that 
these results will encourage more research into the overlap between these two conditions, 
particularly with a view to improving understanding of the risk factors for co-morbidity. This 
study indicates that there may be particular risk factors that predispose an individual to 
developing both an ASD and later a psychotic illness, but much of the current 
conceptualisation regarding the relationship between the conditions has focused on 
differentiating them. It is only by studying people who are affected by both conditions that a 
true understanding of the co-morbidity can be reached. Due to complications regarding 
categorical approaches to the diagnosis of complex conditions such as ASD and psychosis, it 
is also important to consider that such future study may benefit from classifying individuals 
on relevant symptom dimensions rather than diagnoses. Genetic study is much better suited to 
this type of approach, as genetic differences have a cumulative and interactive effect rather 
than mapping perfectly onto behaviourally defined syndromes. It may be that genetic 
variation such as that reported in the current study could in future help inform, in a top-down 
fashion, our diagnosis or understanding of psychiatric conditions. 
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